三星医疗
(601567)
| 流通市值：311.54亿 | | | 总市值：311.55亿 |
| 流通股本：14.11亿 | | | 总股本：14.11亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,630,793,866.31 | 14,600,478,206.12 | 10,433,714,281.29 | 6,997,465,533.74 |
| 营业收入 | 3,630,793,866.31 | 14,600,478,206.12 | 10,433,714,281.29 | 6,997,465,533.74 |
| 二、营业总成本 | 3,129,719,427.73 | 12,231,892,536.68 | 8,580,662,700.55 | 5,848,534,696.67 |
| 营业成本 | 2,581,339,583.91 | 9,530,646,989.31 | 6,655,350,057.66 | 4,575,564,451.09 |
| 税金及附加 | 16,343,496.31 | 94,914,144.68 | 66,979,224.48 | 42,612,901.31 |
| 销售费用 | 275,722,361.36 | 1,016,914,785.27 | 708,649,087.89 | 488,593,822.5 |
| 管理费用 | 185,589,270.36 | 907,462,644.87 | 658,677,578.27 | 410,117,379.28 |
| 研发费用 | 117,042,069.26 | 523,326,835.38 | 413,019,007.29 | 277,566,342.29 |
| 财务费用 | -46,317,353.47 | 158,627,137.17 | 77,987,744.96 | 54,079,800.2 |
| 其中:利息费用 | 33,387,710.86 | 95,000,557.44 | 73,174,347.78 | 53,059,895.79 |
| 其中:利息收入 | 10,267,105.72 | 75,791,055.47 | 55,838,778.46 | 51,589,604.25 |
| 加:公允价值变动收益 | 71,839.66 | -172,769,034.39 | -76,740,042.89 | -49,957,542.6 |
| 加:投资收益 | 63,773,525.28 | 229,188,040.9 | 177,637,485.16 | 128,573,815.19 |
| 资产处置收益 | -270,075.28 | -35,698.18 | -248,929.17 | 190,888.03 |
| 资产减值损失(新) | -8,258,083.79 | -56,494,387.01 | -29,658,832.7 | -14,588,801.01 |
| 信用减值损失(新) | -28,873,380.73 | -31,489,568.08 | -23,622,575.74 | -10,880,217.42 |
| 其他收益 | 39,622,271.62 | 248,148,144.52 | 176,224,563.02 | 113,234,330.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 567,140,535.34 | 2,585,133,167.2 | 2,076,643,248.42 | 1,315,503,309.8 |
| 加:营业外收入 | 3,746,360.96 | 122,232,451.98 | 61,930,639.73 | 56,996,236.55 |
| 减:营业外支出 | 2,295,040.12 | 34,808,996.58 | 20,866,731.81 | 13,855,912.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 568,591,856.18 | 2,672,556,622.6 | 2,117,707,156.34 | 1,358,643,633.59 |
| 减:所得税费用 | 88,106,715.22 | 399,319,160.25 | 294,927,746.69 | 204,546,725.11 |
| 六、净利润 | 480,485,140.96 | 2,273,237,462.35 | 1,822,779,409.65 | 1,154,096,908.48 |
| 持续经营净利润 | 480,485,140.96 | 2,273,237,462.35 | 1,822,779,409.65 | 1,154,096,908.48 |
| 归属于母公司股东的净利润 | 489,308,019.24 | 2,259,517,910.58 | 1,815,696,160.26 | 1,150,008,819.85 |
| 少数股东损益 | -8,822,878.28 | 13,719,551.77 | 7,083,249.39 | 4,088,088.62 |
| (一)基本每股收益 | 0.35 | 1.6 | 1.29 | 0.81 |
| (二)稀释每股收益 | 0.35 | 1.6 | 1.29 | 0.81 |
| 八、其他综合收益 | 14,203,090.27 | -3,372,669.3 | 1,812,403.58 | 10,108,329.32 |
| 归属于母公司股东的其他综合收益 | 15,267,346.55 | -2,000,312.76 | -7,082,179.12 | 11,773,004.66 |
| 九、综合收益总额 | 494,688,231.23 | 2,269,864,793.05 | 1,824,591,813.23 | 1,164,205,237.8 |
| 归属于母公司股东的综合收益总额 | 504,575,365.79 | 2,257,517,597.82 | 1,808,613,981.14 | 1,161,781,824.51 |
| 归属于少数股东的综合收益总额 | -9,887,134.56 | 12,347,195.23 | 15,977,832.09 | 2,423,413.28 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |